Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades GAN to Hold, Announces $2 Price Target

Jefferies analyst David Katz downgrades GAN (NASDAQ:GAN) from Buy to Hold and announces $2 price target.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Jefferies analyst David Katz downgrades GAN (NASDAQ:GAN) from Buy to Hold and announces $2 price target.

Stifel Initiates Coverage On Intel with Hold Rating, Announces Price Target of $32

By Benzinga Newsdesk

Today, 3:15 AM

Stifel analyst Ruben Roy initiates coverage on Intel (NASDAQ:INTC) with a Hold rating and announces Price Target of $32.

INTC

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

By Vandana Singh

Today, 3:15 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The…

CORT

Needham Maintains Buy on Onto Innovation, Raises Price Target to $75

By Benzinga Newsdesk

Today, 3:15 AM

Needham analyst Quinn Bolton maintains Onto Innovation (NYSE:ONTO) with a Buy and raises the price target from $72 to $75.

ONTO

BWS Financial Initiates Coverage On Immersion with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

Today, 3:15 AM

BWS Financial analyst Hamed Khorsand initiates coverage on Immersion (NASDAQ:IMMR) with a Buy rating and announces Price Target of $11.

IMMR

Jefferies Downgrades GAN to Hold, Announces $2 Price Target

Related Posts

Stifel Initiates Coverage On Intel with Hold Rating, Announces Price Target of $32

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

Needham Maintains Buy on Onto Innovation, Raises Price Target to $75

BWS Financial Initiates Coverage On Immersion with Buy Rating, Announces Price Target of $11